tldrdailynews.com logo

Inflammation-Driven Depression Gets a New Target in Small Trial

1 min read
Source: ScienceDaily
Inflammation-Driven Depression Gets a New Target in Small Trial
Photo: ScienceDaily
TL;DR

A small randomized trial (n=30) tested tocilizumab, an IL-6 blocker used for inflammatory diseases, in treatment-resistant depression with signs of inflammation. Participants receiving the drug showed greater improvement in depression, fatigue, anxiety, and quality of life, with a higher remission rate (54% vs. 31%) and an NNT of 5, suggesting a potential immune-based approach to treating depression, though larger phase III trials are needed to confirm efficacy and safety.

Topics:healthhealth-and-medicine#depression#health-and-medicine#il-6#immunotherapy#inflammation#tocilizumab
Share this article
  1. New depression treatment targets the immune system instead of the brain  ScienceDaily
  2. A Common Arthritis Drug Appears to Work When Antidepressants Don't  ScienceAlert
  3. Immunotherapy could be used to treat depression, early trial suggests  The Guardian
  4. Clinical trial suggests an anti-inflammatory drug could relieve difficult-to-treat depression  PsyPost
  5. IL-6 Drug Promising in Depression; U.S. More Anxious; AI Risks in Addiction Medicine  MedPage Today

Want the full story? Read the original reporting

Read on ScienceDaily